<DOC>
	<DOCNO>NCT00209664</DOCNO>
	<brief_summary>To assess usefulness irinotecan plus S-1 therapy base antitumor effect survival period . perform phase II study combination patient inoperable postoperative gastric cancer</brief_summary>
	<brief_title>Phase II Study Oral S-1 Plus Irinotecan Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description>A multicenter Open-label , single-arm , phase II clinical trial conduct patient histological stage IV gastric cancer give irinotecan plus S-1 . The usefulness regimens 1st line therapy gastric cancer evaluate disease-free survival rate ( DFR ) , overall survival rate ( OS ) , incidence severity adverse event .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>ãƒ» Eligibility criterion 1 . Histological diagnosis gastric adenocarcinoma . 2 . Measurable assessable lesion . 3 . Age : 18 ~ 75 year . 4 . Performance Status ( ECOG ) : 0 ~ 2 . 5 . No prior chemotherapy one regimen previous chemotherapy ( washout period &gt; 4 week final day previous therapy ) . Adjuvant chemotherapy define previous therapy . 6 . No history treatment CPT11 S1 . 7 . No history radiotherapy abdomen . 8 . Oral intake S1 possible . 9 . Adequate function major organ ( bone marrow , heart , lung , liver etc. ) . WBC 3,500/mm3 12,000/mm3 . Hb 10.0 g/dl . Platelet count 100,000/mm3 . GOT GPT 2.5times upper limit normal ( exclude liver metastasis ) . TBil 2.0mg/dl . Creatinine &lt; 1.5 mg/dl ( 1.0 ~ 1.5 mg/dl , dose S1 decrease accord dose reduction criterion allow registration trial ) . Normal ECG ( consider clinically unimportant arrhythmias ischemic change ) . ( 10 ) Predicted survival &gt; 3 month . ( 11 ) Able give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2004</verification_date>
	<keyword>Irinotecan , S-1 , Phase II , gastric cancer</keyword>
</DOC>